Notice concerning licensing and fundingAugust 04, 2016
Innovation Network Corporation of Japan
Meiji Seika Pharma Co., Ltd.
Curadim Pharma Co., Ltd.
Announcement of drug candidate licensing and investment in Curadim Pharma Co., Ltd., a new company that develops new drugs for treatment of refractory diseases
TOKYO, August 4, 2016: Meiji Seika Pharma Co., Ltd. (Meiji) and Innovation Network Corporation of Japan (INCJ) announced today that Meiji have provided Curadim Pharma Co., Ltd. (Curadim Pharma) with the license to Meiji’s multiple sclerosis treatment drug candidate (compound number: CP9531), which targets the sphingosine-1-phosphate receptor, and rights to its R&D, manufacturing and sales worldwide, and INCJ will invest up to 1 billion yen to provide Curadim Pharma with the necessary funding to support future R&D.